Form 4: Kymera Therapeutics Director Exercises Options and Sells Shares Under Pre-Arranged Trading Plan

Elena Ridloff, a Director at Kymera Therapeutics, Inc., executed a pre-planned transaction on June 11, 2025, exercising stock options and simultaneously selling the acquired common stock for a significant profit.

Summary

• On June 11, 2025, Elena Ridloff, a Director of Kymera Therapeutics, Inc. (KYMR), acquired 4,500 shares of common stock by exercising stock options at a price of $20.29 per share.
• Concurrently, Ms. Ridloff disposed of these 4,500 shares of common stock at a price of $50.00 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by the reporting person on November 25, 2024.
• The stock options exercised were part of an award that vests in thirty-six equal monthly installments, with the vesting commencement date being June 29, 2022, contingent on continued service.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the director successfully monetized vested options at a favorable price, indicating personal financial gain. For the company, it's a neutral event as it's a routine insider transaction under a pre-planned arrangement.

Positives

• The Director realized a substantial profit from the transactions, acquiring shares at $20.29 and selling them at $50.00, indicating a gain of $29.71 per share.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which demonstrates a structured and pre-determined approach to insider trading, reducing concerns about opportunistic selling.

Negatives

• The sale of shares by a director, even under a 10b5-1 plan, could be perceived by some investors as a lack of confidence, although this is mitigated by the pre-planned nature of the transaction.

Industry Context

This filing is a standard disclosure of an insider transaction, common across all publicly traded companies, particularly in the biotechnology sector where executive compensation often includes equity-based incentives like stock options.

Related Party Transactions

• The reported transactions involve a director of Kymera Therapeutics, Inc. exercising stock options and selling shares, which constitutes a related party transaction as it is an insider dealing in company securities.

Stakeholder Impact

• Shareholders: May observe a director selling shares, but the existence of a 10b5-1 plan typically mitigates concerns about the sale signaling a lack of confidence in the company's future performance.
• Employees: No direct impact mentioned.

Key Dates

Keywords

Kymera Therapeutics, KYMR, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Director Transaction, Rule 10b5-1 Plan, Elena Ridloff